Saliladja, Sabriya T.

HRN: 23-34-10  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/29/2023
AMPICILLIN 250MG (VIAL)
07/29/2023
08/04/2023
IVTT
160mg
Q12
TC Fecal Impaction
Checking Final Appropriateness 
07/29/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
07/29/2023
08/04/2023
IVTT
50mg
Q24
Tc Fecal Impaction
Checking Final Appropriateness 
07/31/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
07/31/2023
08/07/2023
IVTT
48mg
Q12
TC Hirschsprung Disease
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: